Trevi Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Trevi Therapeutics, Inc. (TRVI) on October 15, 2021, with the earliest event reported on the same date. The filing details a private placement transaction and the satisfaction of a debt covenant.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of common stock and warrants.
- Investor: New Enterprise Associates 16, L.P. (existing stockholder).
- Securities Issued: 1,851,852 shares of Common Stock and warrants to purchase 3,703,704 shares of Common Stock.
- Pricing: Combined price of $1.62 per share and accompanying warrants.
- Gross Proceeds: Approximately $3.0 million.
- Warrant Terms: Exercise price of $1.37 per share; exercisable immediately. Half expire in 3.5 years, half in 7 years from the closing date (October 18, 2021).
- Liquidity Impact: Proceeds, combined with amounts raised since June 1, 2021, satisfied a loan covenant with Silicon Valley Bank requiring $15.0 million in net equity proceeds by October 31, 2021.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement and a Registration Rights Agreement. Under the Registration Rights Agreement, the Company agreed to file a registration statement for the resale of the shares and warrant shares within 15 days of the effectiveness of a Form S-3 filed on October 15, 2021. The agreement includes liquidated damages provisions of 1.0% per 30-day period (capped at 10.0%) if registration obligations are not met.
Outlook, Risks, and Contingencies
The filing includes standard forward-looking statements regarding product development, clinical trials, and cash runway. Key risks identified include:
- Uncertainties regarding the success, cost, and timing of clinical trials.
- Ability to continue as a going concern.
- Impact of the COVID-19 pandemic on clinical operations.
- Regulatory developments in the U.S. and foreign countries.
The filing does not provide specific revenue, profit, or cash flow figures for the period, as this is a transactional report rather than a periodic financial statement.
Investor Verification Checklist
- Verify the closing date of the private placement (October 18, 2021) and the actual receipt of the $3.0 million gross proceeds.
- Confirm the status of the Form S-3 registration statement filed on October 15, 2021, to ensure the liquidated damages clause in the Registration Rights Agreement is not triggered.
- Review the Company's most recent Form 10-Q to assess the total cash runway following this capital raise.
- Monitor the Company's progress in meeting the $15.0 million equity raise covenant with Silicon Valley Bank by the October 31, 2021 deadline.